Case Report (n=1)
No
Prompt recognition of a short QTc interval is essential in patients with polymorphic ventricular tachycardia, as targeted pharmacologic therapy with quinidine is highly effective at normalizing the QT interval and suppressing malignant arrhythmias.
May support quinidine in short QT syndrome; leaves open prospective validation before practice change.
BACKGROUND: We present a case of short QT syndrome (SQTS) initially manifesting as atrial fibrillation (AF) and degenerating to polymorphic ventricular tachycardia (PMVT), successfully managed with quinidine. CASE SUMMARY: A 66-year-old man presented with palpitations and was found to be in AF with a QTc interval of 335 ms. He developed PMVT with hemodynamic collapse, requiring 3 successive defibrillation shocks. Refractory to amiodarone and lidocaine, he met Gollob criteria for SQTS. He was successfully managed with oral quinidine, resulting in QTc normalization to 430 ms. A secondary prevention implantable cardioverter-defibrillator was implanted. Genetic testing was unrevealing. He remained arrhythmia-free at 6 months. DISCUSSION: With an estimated prevalence of 0.02%, SQTS is frequently underrecognized. This case underscores the specific efficacy of quinidine in normalizing the QT interval and suppressing malignant ventricular arrhythmias in SQTS. TAKE-HOME MESSAGE: Prompt recognition of a short QTc interval is crucial in patients presenting with PMVT, as diagnosis directs targeted pharmacologic therapy with quinidine.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2026) conducted a case report in Short QT Syndrome (n=1). Quinidine was evaluated on QTc interval normalization and arrhythmia suppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: